Kupriyanova E A, Abdulkhakov S R, Ismagilova R К, Safina D D, Akhtereeva A R, Galimova R R, Safin A G, Grigoryeva T V, Abdulkhakov R А
Kazan (Volga region) Federal University.
Kazan State Medical University.
Ter Arkh. 2024 Sep 14;96(8):739-743. doi: 10.26442/00403660.2024.08.202813.
One of the reasons for the decrease of eradication effectiveness is its resistance to antibiotics.
To examine the prevalence of point mutations responsible for clarithromycin and levofloxacin resistance among the patients with upper gastrointestinal (GI) tract disorders in Kazan.
The study included 203 patients with symptoms of dyspepsia who underwent upper GI endoscopy at the University Hospital of Kazan Federal University (Kazan, Russia) in 2019-2021. DNA isolation from gastric antrum mucosal biopsies was performed using PureLink Genomic DNA Mini Kits (Thermo Fisher Scientific, USA). Polymerase chain reaction was performed using primers specific for the V-region of the gene and the A subunit DNA gyrase encoding gene region. The sequencing of obtained DNA fragments was performed on 3730 DNA Analyzer. The sequences were searched for point mutations responsible for resistance to clarithromycin (A2143G, A2142G and A2142C193 mutations) and levofloxacin (mutations of the gene).
was detected in 47.78% of biopsy specimens using polymerase chain reaction. The proportion of strains with mutations leading to clarithromycin resistance was 17.53%. Amino acid substitutions in the gene were found in 12.37% of samples. In case of two strains (2.06%), dual resistance to clarithromycin and levofloxacin was found.
So high incidence of mutations underlying the development of resistance to clarithromycin and levofloxacin was observed among examined patients in Kazan.
根除有效性下降的原因之一是其对抗生素的耐药性。
研究喀山地区上消化道疾病患者中导致克拉霉素和左氧氟沙星耐药的点突变的流行情况。
该研究纳入了203例有消化不良症状的患者,这些患者于2019年至2021年在喀山联邦大学大学医院(俄罗斯喀山)接受了上消化道内镜检查。使用PureLink基因组DNA微型试剂盒(美国赛默飞世尔科技公司)从胃窦黏膜活检组织中提取DNA。使用针对该基因V区和编码DNA旋转酶A亚基基因区域的特异性引物进行聚合酶链反应。在3730 DNA分析仪上对获得的DNA片段进行测序。在序列中搜索导致对克拉霉素耐药的点突变(A2143G、A2142G和A2142C193突变)和左氧氟沙星(该基因的突变)。
使用聚合酶链反应在47.78%的活检标本中检测到该菌。导致克拉霉素耐药的突变菌株比例为17.53%。在12.37%的样本中发现了该基因的氨基酸替代。在两株该菌(2.06%)中发现了对克拉霉素和左氧氟沙星的双重耐药。
在喀山接受检查的患者中,观察到导致对克拉霉素和左氧氟沙星耐药的突变发生率很高。